Journal article
Smoking cessation and outcome after ischemic stroke or TIA
Katherine A Epstein, Catherine M Viscoli, J David Spence, Lawrence H Young, Silvio E Inzucchi, Mark Gorman, Brett Gerstenhaber, Peter D Guarino, Anand Dixit, Karen L Furie, Walter N Kernan
NEUROLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017
Abstract
OBJECTIVE: To assess whether smoking cessation after an ischemic stroke or TIA improves outcomes compared to continued smoking. METHODS: We conducted a prospective observational cohort study of 3,876 nondiabetic men and women enrolled in the Insulin Resistance Intervention After Stroke (IRIS) trial who were randomized to pioglitazone or placebo within 180 days of a qualifying stroke or TIA and followed up for a median of 4.8 years. A tobacco use history was obtained at baseline and updated during annual interviews. The primary outcome, which was not prespecified in the IRIS protocol, was recurrent stroke, myocardial infarction (MI), or death. Cox regression models were used to assess the dif..
View full abstractGrants
Awarded by National Institute of Neurological Disorders and Stroke (NINDS), NIH
Funding Acknowledgements
This work (and the original IRIS trial) was supported by a grant (U01NS044876) from the National Institute of Neurological Disorders and Stroke (NINDS), NIH. Pioglitazone and placebo for the original IRIS trial were provided by Takeda Pharmaceuticals. The NINDS and Takeda Pharmaceuticals had no role in data collection, data analysis, data interpretation, or writing of this report.